Novel PDAC Murine Homografts for I/O Drug Development

Preclinical, immunocompetent models are needed for immunotherapy drug development in pancreatic ductal adenocarcinoma (PDAC). This cancer type shows resistance to standard of care therapies and single agent immune checkpoint inhibitors, leaving combination immunotherapies as the next treatment route researchers would like to assess.